Table 2 Potential DDIs with severe category risk according to severity indicated by Micromedex and Lexi-Interact
Antimicrobials | Other drug | n | Lexi-Interact | Micromedex | Potential clinical consequence |
|---|---|---|---|---|---|
Linezolid | Dopamine | 25 | None | Contraindicated | Increased hypertensive effects |
Voriconazole | Budesonide for inhalation | 15 | X-Moderate | None | Increased serum concentration of budesonide |
Linezolid | Metoclopramide | 7 | X-Moderate | None | Increased hypertensive effect of linezolid |
Levofloxacin | Amiodarone | 5 | X-Major | None | Increased QT prolongation of amiodarone |
Linezolid | Tramadol | 4 | None | Contraindicated | Increased risk of serotonin syndrome or opioid toxicity and seizures |
Linezolid | Epinephrine | 4 | None | Contraindicated | Increased hypertensive effects |
Moxifloxacin | Amiodarone | 4 | X-Major | None | Increased QT prolongation of moxifloxacin |
Linezolid | Morphine | 4 | X-Moderate | None | Increased adverse/toxic effect of morphine (systemic) |
Linezolid | Dobutamine | 4 | D-Moderate | Contraindicated | Increased hypertensive effects |
Fluconazole | Ritonavir | 3 | None | Contraindicated | Increased ritonavir exposure and an increased risk of QT prolongation |
Voriconazole | Amiodarone | 3 | X-Major | None | Increased QT prolongation of voriconazole and Increased serum concentration of amiodarone |
Fluconazole | Amiodarone | 3 | D-Major | Contraindicated | Increased QT prolongation and serum concentration of amiodarone |
Linezolid | Pethidine | 2 | None | Contraindicated | Increased risk of serotonin syndrome or opioid toxicity |
Fluconazole | Ondansetron | 2 | None | Contraindicated | increased ondansetron exposure and an increased risk of QT prolongation |
Linezolid | Pseudoephedrine | 2 | None | Contraindicated | Hypertensive crisis (headache, hyperpyrexia, hypertension) |
Amikacin | Mannitol | 2 | X-Major | None | Increased Nephrotoxic effect of aminoglycosides |
Levofloxacin | Domperidone | 2 | X-Moderate | Major | Increased QT prolongation of domperidone |
Voriconazole | Papaverine | 2 | X-Major | None | Increased QT prolongation of voriconazole and Increased serum concentration of papaverine |
Voriconazole | Ivabradine | 1 | X-Moderate | Contraindicated | Increased exposure of ivabradine and increased risk of QT prolongation |
Fluconazole | Domperidone | 1 | X-Major | Contraindicated | Increased domperidone exposure and an increased risk of QT prolongation |
Voriconazole | Ritonavir | 1 | None | Contraindicated | Decreased plasma concentrations of voriconazole with high-dose and, to a lesser extent, low-dose ritonavir, and risk of reduced voriconazole efficacy |
Voriconazole | Domperidone | 1 | X-Major | None | Increased QT prolongation and serum concentration of domperidone |